Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory bowel disease (IBD). This acquisition underscores Lilly’s strategic expansion into the gastroenterology sector. The transaction, valued at $57 per share, is a significant premium over Morphic’s recent stock prices, reflecting […]